Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

rolapitant

- PMLiVE

Novartis’ Kisqali granted MHRA approval to treat early breast cancer patients

The drug is already approved in the UK to treat advanced cases of the disease

- PMLiVE

Merck’s adult-specific pneumococcal vaccine Capvaxive recommended by CHMP

Diseases caused by Streptococcus pneumoniae bacteria are considered a “major public health problem” by WHO

- PMLiVE

BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer

Hepatocellular carcinoma accounts for approximately 90% of all liver cancer cases globally

- PMLiVE

AstraZeneca’s Imfinzi recommended by CHMP to treat small cell lung cancer

Approximately 30% of small cell lung cancer patients have limited-stage disease

- PMLiVE

J&J’s subcutaneous Rybrevant receives positive CHMP opinion for advanced lung cancer

The formulation significantly reduces administration time compared to the approved intravenous version

- PMLiVE

Sanofi’s Sarclisa combination approved by MHRA for newly diagnosed multiple myeloma

An estimated 5,900 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Sanofi’s Sarclisa granted EC approval to treat newly diagnosed multiple myeloma

Approximately 46,000 cases of the disease are expected to be diagnosed in Europe in 2025

- PMLiVE

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

- PMLiVE

J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

The deal gives the company access to a range of central nervous system disorder drugs

- PMLiVE

Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma

Approximately 32,000 people are diagnosed with the haematological malignancy in the US every year

- PMLiVE

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal

The inflammatory skin disorder affects more than 9.6 million children and 16.5 million adults in the US

- PMLiVE

Novartis’ investigational spinal muscular atrophy gene therapy shows promise in late-stage study

An estimated one in 10,000 infants globally are affected by the rare neuromuscular disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links